BACKGROUND: Neoadjuvant chemotherapy (NAC) before surgery has already shown the therapy effectiveness inpatients with cervical cancer. The present meta-analysis was conducted to determine whether the response to NAC predicts for prognosis. METHODS: Systematic computerized searches of the Pub-Med and Web of Knowledge were performed. Prognosis outcomes included progression-free survival (PFS), and overall survival (OS). The pooled odd ratio (OR) was estimated by using fixed-effect model or random-effect model according to heterogeneity between studies. RESULTS: Eighteen studies with 1,785 patients were included. Cisplatin-based NAC treatments were most commonly used. The clinical response rate ranged from 48.4 to 93.0 %, and the pathological response rate ranged from 27.6 to 30.6 %. The pooled ORs estimating the association of PFS with NAC response were 5.707 (95 % CI3.564–9.137), 6.798 (95 % CI 4.716–9.799), 6.327 (95 %CI 4.398–9.102), and 5.214 (95 % CI 3.748–7.253) at 1-,2-, 3-, and 5-year follow-up, respectively, and the pooled ORs estimating the association of OS with NAC response were 6.179 (95 % CI 3.390–11.264), 9.155 (95 % CI5.759–14.555), 8.431 (95 % CI 5.667–12.543), and 5.785(95 % CI 4.124–8.115) at 1-, 2-, 3-, and 5-year follow-up,respectively. No obvious statistical heterogeneity was detected. Funnel plots and Egger’s tests did not reveal publication bias. Sensitivity analysis showed the results of meta-analysis were robust. CONCLUSION: This meta-analysis confirms that response to NAC is an indicator for PFS and OS, and suggests that patients-achieving response of NAC before surgery predicts favorable prognosis for cervical cancer patients.
BACKGROUND: Neoadjuvant chemotherapy (NAC) before surgery has already shown the therapy effectiveness inpatients with cervical cancer. The present meta-analysis was conducted to determine whether the response to NAC predicts for prognosis. METHODS: Systematic computerized searches of the Pub-Med and Web of Knowledge were performed. Prognosis outcomes included progression-free survival (PFS), and overall survival (OS). The pooled odd ratio (OR) was estimated by using fixed-effect model or random-effect model according to heterogeneity between studies. RESULTS: Eighteen studies with 1,785 patients were included. Cisplatin-based NAC treatments were most commonly used. The clinical response rate ranged from 48.4 to 93.0 %, and the pathological response rate ranged from 27.6 to 30.6 %. The pooled ORs estimating the association of PFS with NAC response were 5.707 (95 % CI3.564–9.137), 6.798 (95 % CI 4.716–9.799), 6.327 (95 %CI 4.398–9.102), and 5.214 (95 % CI 3.748–7.253) at 1-,2-, 3-, and 5-year follow-up, respectively, and the pooled ORs estimating the association of OS with NAC response were 6.179 (95 % CI 3.390–11.264), 9.155 (95 % CI5.759–14.555), 8.431 (95 % CI 5.667–12.543), and 5.785(95 % CI 4.124–8.115) at 1-, 2-, 3-, and 5-year follow-up,respectively. No obvious statistical heterogeneity was detected. Funnel plots and Egger’s tests did not reveal publication bias. Sensitivity analysis showed the results of meta-analysis were robust. CONCLUSION: This meta-analysis confirms that response to NAC is an indicator for PFS and OS, and suggests that patients-achieving response of NAC before surgery predicts favorable prognosis for cervical cancerpatients.
Authors: Linus T Chuang; Sarah Temin; Rolando Camacho; Alfonso Dueñas-Gonzalez; Sarah Feldman; Murat Gultekin; Vandana Gupta; Susan Horton; Graciela Jacob; Elizabeth A Kidd; Kennedy Lishimpi; Carolyn Nakisige; Joo-Hyun Nam; Hextan Yuen Sheung Ngan; William Small; Gillian Thomas; Jonathan S Berek Journal: J Glob Oncol Date: 2016-05-25